Renaud Capdeville

Renaud Capdeville

UNVERIFIED PROFILE

Are you Renaud Capdeville?   Register this Author

Register author
Renaud Capdeville

Renaud Capdeville

Publications by authors named "Renaud Capdeville"

Are you Renaud Capdeville?   Register this Author

31Publications

641Reads

47Profile Views

A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.

Anticancer Drugs 2007 Feb;18(2):219-25

Department of General Medical Oncology, UZ Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e328010ef5bDOI Listing
February 2007

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.

Cancer Chemother Pharmacol 2004 Oct 8;54(4):290-4. Epub 2004 May 8.

Novartis Pharma AG, 4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0832-zDOI Listing
October 2004

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

J Clin Oncol 2004 Mar;22(5):935-42

Clinical Pharmacology, Novartis, One Health Plaza, Building 419, Room 2368, East Hanover, NJ 07936-1080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.03.050DOI Listing
March 2004

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.

Cancer Chemother Pharmacol 2004 Feb 7;53(2):102-6. Epub 2003 Nov 7.

Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0722-9DOI Listing
February 2004

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.

J Clin Pharmacol 2004 Feb;44(2):158-62

Clinical Pharmacology, Novartis Pharmaceuticals Corporation, 180 Park Avenue, Building 105, Room 2W212, Florham Park, NJ 07936-1080, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1177/0091270003262101
Publisher Site
http://dx.doi.org/10.1177/0091270003262101DOI Listing
February 2004

Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Clin Cancer Res 2004 Jan;10(1 Pt 1):155-65

Clinical Pharmacogenetics Department, Novartis Pharmaceuticals Corporation, Gaithersburg, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.ccr-0784-3DOI Listing
January 2004

Imatinib: a targeted clinical drug development.

Semin Hematol 2003 Apr;40(2 Suppl 2):15-20

Novartis Oncology, Novartis Pharma AG, Basel, Switzerland; and Novartis Oncology, Novartis Pharmaceutical Corp, Florham Park, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/shem.2003.50037DOI Listing
April 2003

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.

Leuk Lymphoma 2002 Dec;43(12):2281-9

Center for Hematologic Oncology, Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1042819021000039992DOI Listing
December 2002

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

Blood 2002 Sep;100(5):1628-33

Leukemia Center, Oregon Health and Science University Cancer Institute, Portland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2002-03-0777DOI Listing
September 2002

Imatinib: the first 3 years.

Eur J Cancer 2002 Sep;38 Suppl 5:S77-82

International Clinical Research Oncology, Novartis Pharma AG, CH-4056 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0959-8049(02)80607-4DOI Listing
September 2002

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.

Nat Rev Drug Discov 2002 Jul;1(7):493-502

Novartis Pharma AG, S-27 2.033, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrd839
Publisher Site
http://dx.doi.org/10.1038/nrd839DOI Listing
July 2002

Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.

Blood 2002 May;99(9):3465-7

School of Clinical and Laboratory Sciences and the School of Biochemistry and Genetics, University of Newcastle, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.v99.9.3465DOI Listing
May 2002